How long does a patient need to be on metformin before the B12 deficiency is seen? How long after stopping metformin can B12 levels be expected to normalize?

Comment by InpharmD Researcher

Although the specific duration for deficiency varies, the majority of studies suggest that vitamin B12 deficiency linked to metformin use can arise anywhere from 3 months to 5 years. The evidence highlights the significance of dose and duration, correlating higher daily and cumulative doses with decreased cobalamin concentrations. Furthermore, there is evidence indicating an elevated risk of deficiency with each 1 g/d metformin dose increment, particularly among long-term users. Routine monitoring is recommended, especially for those over 60 years and those on metformin for more than 4 years. The precise timing for B12 levels to normalize after stopping metformin is not explicitly addressed in the literature, necessitating regular monitoring and individualized assessment to manage the potential risk of vitamin B12 deficiency associated with metformin use.

Background

According to the American Diabetes Association (ADA) Standards of Care in Diabetes 2023 Guideline, long-term use of metformin can be associated with vitamin B12 deficiency. Although there isn’t a universally agreed-upon frequency for monitoring, it’s worth mentioning that the impact of metformin on vitamin B12 tends to amplify over time where one study observed a notably elevated risk of vitamin B12 deficiency (<150 pmol/L) at 4.3 years. The guidelines suggest that B12 levels should be measured periodically, with an emphasis on monitoring those who have anemia or peripheral neuropathy. They also suggest that those who have been on metformin for more than 4 years or have other risk factors for vitamin B12 deficiency have annual monitoring of B12 levels since the vitamin B12 lowering effect of metformin increases with time. The guidelines do not further delve into the definition of the long-term use or how long after stopping metformin the vitamin B12 levels are expected to normalize. [1]

A 2019 meta-analysis evaluated the associations between metformin use and serum vitamin B12 levels in order to potentially provide guidance on monitoring vitamin B12 levels in these patients. Of the 31 total studies, 23 (N= 5,227) provided information on the duration- and dose-dependent effects of metformin. As expected, patients taking metformin had significantly lower vitamin B12 levels than patients not taking metformin (p<0.00001). Subgroup analyses found this association occurred in patients taking metformin for <1 year (mean difference [MD] -28.94; 95% confidence interval [CI] -55.31 to -2.57 pmol/L; p= 0.03), between 1-3 years (MD -51.11; 95% CI -84.99 to -17.24 pmol/l ;p=0.003), and >3 years (MD -62.11; 95% CI -83.02 to -41.20 pmol/L; p<0.00001). Additionally, the magnitude of vitamin B12 decline increased as the duration of metformin therapy increased. Another subgroup analysis found significant decreases in vitamin B12 concentrations were associated with a mean metformin dose of <2,000 mg/day (MD -40.40; 95% CI -61.32 to -19.48 pmol/L; p=0.00002) as well as ≥2,000 mg/day (MD -66.06; 95% CI -86.32 to -45.80 pmol/L; p<0.00001). There was a greater reduction in serum vitamin B12 in patients taking ≥2,000 mg of metformin daily compared to <2,000 mg. Routine monitoring of vitamin B12 levels is suggested for patients taking metformin based on the available evidence, especially in patients >60 years of age and in patients who have been taking metformin for a long duration. The authors recommend annual monitoring of vitamin B12 levels in patients taking metformin to potentially avoid irreversible complications of vitamin B12 deficiency. [2]

A 2022 meta-analysis aimed to explore the effect of metformin use on vitamin B12 deficiency in patients with type 2 diabetes mellitus (T2DM). The study consisted of 17 studies, including 13 cross-sectional, 3 retrospective cohorts, and 1 case-control study. Significant factors linked to vitamin B12 deficiency in individuals with T2DM and using metformin included the duration of metformin use and a higher metformin dosage. Studies comparing the duration of metformin use showed notable differences between patients who used it for less than 4 years, those using it for 4-10 years, and those with more than 10 years of usage. The findings indicated a significant increase in the likelihood of vitamin B12 deficiency among patients who used metformin for 4-10 years (odds ratio [OR] 2.54, 95% CI 1.22 to 8.54, p= 0.001), and more than 10 years (OR 2.32, 95% CI 1.27 to 4.22, p= 0.001). In addition, individuals using a daily dosage of less than 1,000 mg are less prone to vitamin B12 deficiency compared to those taking 1,000 to 2,000 mg daily (OR 2.58, 95% CI 1.73 to 3.83, p= 0.001) and those with a daily dosage exceeding 2,000 mg (OR 5.89, 95% CI 2.63 to 13.19, p= 0.001). Overall, this study reveals a higher prevalence of vitamin B12 deficiency among patients receiving metformin compared to those not using metformin. Furthermore, factors associated with vitamin B12 deficiency in patients with T2DM and on metformin treatment include the daily metformin dosage and the duration of metformin use. The study did not explore the time it takes to reach a normal level of vitamin B12 after cessation of metformin. [3]

A 2021 review article discussed the association between long-term metformin therapy and vitamin B12 deficiency. It was suggested that metformin impairs vitamin B12 status primarily in a dose and duration-dependent manner. One study revealed that individuals with T2DM using metformin had a higher prevalence of vitamin B12 deficiency (14.1% vs. 4.4%) compared to non-users, with a metformin use duration of 4.9 years. Each 100 mg increase in metformin dose raised the odds of vitamin B12 deficiency by 8%. Another study in 550 T2DM patients using metformin found that higher daily and cumulative doses were strongly linked to lower holotranscobalamin (HoloTC) and cobalamin concentrations, but no association was found with the duration of metformin use. A nested case-control study suggested a more than 2-fold increased risk of vitamin B12 deficiency with each 1 g/d metformin dose increment, particularly in patients using metformin for 3 years or more (OR 2.39; 95% CI 1.46 to 3.91; p = 0.001). In another study involving 2,887 patients with T2DM, the combined effect of metformin dose and duration was assessed. They observed higher percentages of vitamin B12 deficiency (<200 pg/mL and 200-300 pg/mL) in metformin users compared to non-users. Using a metformin usage index (MUI), calculated as the product of daily dose and duration divided by 1,000, a significant association was found between MUI values >5 and a high risk of vitamin B12 deficiency. Adjusted regression analysis revealed the highest risk with MUI > 15, followed by MUI > 10, while the lowest risk was seen in patients with MUI <5. [4], [5], [6], [7]

While several studies indicate that the prevalence of B12 deficiency increases with the duration of metformin use, there is inconsistency in the findings regarding the specific duration required for vitamin B12 deficiency to occur in patients. The majority of studies propose that vitamin B12 deficiency associated with metformin use can manifest anywhere from 3 months to 5 years. Notably, one study observed B12 deficiency as early as 6 weeks into metformin use. [8], [9], [10], [11], [12], [13]

In a cross-sectional study of 1,111 patients with type 2 diabetes, doses of metformin at 1,500 mg/day or greater was associated with significantly greater decrease in vitamin B12 levels compared to metformin daily doses <1000 mg. However, in patients taking multivitamins, vitamin B12 deficiency seemed to occur less often (OR 0.23; p<0.001), suggesting that supplementation may confer protection against deficiency. In this study, the mean duration of metformin use was 10.1 ± 7.0 years (range of 0.5 to 45 years), with a mean daily dose of 1,339 ± 479  mg. Serum vitamin B12 levels demonstrated a negative correlation with metformin dose (r = −0.300, p <0 .001) with no significant correlation to the duration of metformin use (r = 0.030, p =0 .317). Categorizing daily metformin use dose (<1,000, 1,000-1,500, 1,500-2,000, and ≥2,000 mg) revealed a significant decrease in serum vitamin B12 levels as metformin dose increased (p<0.001). However, duration of metformin use categorized as <10, 10-20, and ≥20 years showed no significant correlation with serum vitamin B12 levels. [14]

References:

[1] ElSayed NA, Aleppo G, Aroda VR, et al. 3. Prevention or delay of type 2 diabetes and associated comorbidities: standards of care in diabetes—2023. Diabetes Care. 2023;46(Supplement_1):S41-S48. doi:10.2337/dc23-S003
[2] Yang W, Cai X, Wu H, Ji L. Associations between metformin use and vitamin B12 levels, anemia, and neuropathy in patients with diabetes: a meta-analysis. J Diabetes. 2019;11(9):729-743. doi:10.1111/1753-0407.12900
[3] Kakarlapudi Y, Kondabolu SK, Tehseen Z, et al. Effect of Metformin on Vitamin B12 Deficiency in Patients With Type 2 Diabetes Mellitus and Factors Associated With It: A Meta-Analysis. Cureus. 2022;14(12):e32277. Published 2022 Dec 7. doi:10.7759/cureus.32277
[4] Infante M, Leoni M, Caprio M, Fabbri A. Long-term metformin therapy and vitamin B12 deficiency: An association to bear in mind. World J Diabetes. 2021;12(7):916-931. doi:10.4239/wjd.v12.i7.916
[5] de Groot-Kamphuis DM, van Dijk PR, Groenier KH, Houweling ST, Bilo HJ, Kleefstra N. Vitamin B12 deficiency and the lack of its consequences in type 2 diabetes patients using metformin. Neth J Med. 2013;71(7):386-390.
[6] Beulens JW, Hart HE, Kuijs R, Kooijman-Buiting AM, Rutten GE. Influence of duration and dose of metformin on cobalamin deficiency in type 2 diabetes patients using metformin. Acta Diabetol. 2015;52(1):47-53. doi:10.1007/s00592-014-0597-8
[7] Shivaprasad C, Gautham K, Ramdas B, Gopaldatta KS, Nishchitha K. Metformin Usage Index and assessment of vitamin B12 deficiency among metformin and non-metformin users with type 2 diabetes mellitus. Acta Diabetol. 2020;57(9):1073-1080. doi:10.1007/s00592-020-01526-4
[8] Herbert L, Ribar A, Mitchell S, Phillips C. Discovering metformin-induced vitamin B12 deficiency in patients with type 2 diabetes in primary care. J Am Assoc Nurse Pract. 2019;33(2):174-180. Published 2019 Oct 20. doi:10.1097/JXX.0000000000000312
[9] Iftikhar R, Kamran SM, Qadir A, Iqbal Z, bin Usman H. Prevalence of vitamin B12 deficiency in patients of type 2 diabetes mellitus on metformin: a case control study from Pakistan. Pan Afr Med J. 2013;16:67. Published 2013 Oct 25. doi:10.11604/pamj.2013.16.67.2800
[10] Kancherla V, Elliott JL Jr, Patel BB, et al. Long-term Metformin Therapy and Monitoring for Vitamin B12 Deficiency Among Older Veterans. J Am Geriatr Soc. 2017;65(5):1061-1066. doi:10.1111/jgs.14761
​​[11] Kang D, Yun JS, Ko SH, et al. Higher prevalence of metformin-induced vitamin B12 deficiency in sulfonylurea combination compared with insulin combination in patients with type 2 diabetes: a cross-sectional study. PLoS One. 2014;9(10):e109878. Published 2014 Oct 9. doi:10.1371/journal.pone.0109878
[12] Chapman LE, Darling AL, Brown JE. Association between metformin and vitamin B12 deficiency in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Metab. 2016;42(5):316-327. doi:10.1016/j.diabet.2016.03.008
[13] Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101(4):1754-1761. doi:10.1210/jc.2015-3754
[14] Kim J, Ahn CW, Fang S, Lee HS, Park JS. Association between metformin dose and vitamin B12 deficiency in patients with type 2 diabetes. Medicine (Baltimore). 2019;98(46):e17918. doi:10.1097/MD.0000000000017918

Literature Review

A search of the published medical literature revealed 2 studies investigating the researchable question:

How long does a patient need to be on metformin before the B12 deficiency is seen? How long after stopping metformin can B12 levels be expected to normalize?

Please see Tables 1-2 for your response.


 

Assessment of Vitamin B12 Deficiency and B12 Screening Trends for Patients on Metformin: A Retrospective Cohort Case Review

Design

Single-center, retrospective, observational, database analysis

N= 13,489

Objective

To investigate the use of vitamin B12 testing in a large cohort of patients on metformin and assess the benefit of formulating screening recommendations for vitamin B12 deficiency

Inclusion Criteria

Insured patients ≥18 years old who had more than 1 year of metformin use between 1 January 2010 and 1 October 2016; filled at least two consecutive prescriptions of metformin

Exclusion Criteria

History of vitamin B12 deficiency, a single prescription of metformin filled, first metformin prescription filled within 30 days of insurance

Methods

Data were collected via access to an administrative database of a non-profit health insurance plan offered by a large hospital system in Michigan. Age was categorized into quintiles (18-39 years old, 40-49 years old, 50-64 years old, 65-70 years old, and >80 years old). Subgroups of confounding variables included malabsorption syndromes and prescription proton pump inhibitor (PPI) use.

To be recommended for routine screening, vitamin B12 must meet certain criteria based on Wilson and Jungner's principles: (1) the disease is appropriate for screening; (2) screening is feasible and effective; and (3) the screening test is valid and widely available.

Duration

January 1, 2010 to December 31, 2018

Outcome Measures

Primary outcome: incidence of B12 deficiency diagnosed in patients on metformin

Secondary outcomes: occurrence of B12 testing in the patient population on metformin

Baseline Characteristics

 

Metformin (N= 13,489)

     

Age, years

18-39

40-49

50-64

65-79

>80

 

830 (6.2%)

1,716 (12.7%)

5,828 (43.2%)

4,196 (31.1%)

919 (6.8%)

     

Female

7,242 (53.7%)      

Race

African-American

Caucasian

 

5,409 (40.1%)

5,858 (43.4%)

     

Confounders

Malabsorption disorders

PPI use

 

684 (5.1%)

3,957 (29.3%)

     

Results

 

Deficiency

Mean days to B12 deficiency

Ever tested

Mean days to test

All patients 

202/6,051 (3.3%)

1,926

6,051 (44.9%)

972

Age, years

18-39

40-49

50-64

65-79

>80 

 

3 (1.0%)

12 (2.1%)

64 (2.8%)

99 (4.3%)

24 (4.2%)

 

2,686

2,367

2,019

1,894

1,492 

 

292 (35.2%)

581 (33.9%)

2,316 (39.7%)

2,285 (54.5%)

577 (62.8%)

 

929

942

1,050

952

785

Gender

Male

Female

 

81 (3.1%)

121 (3.5%)

 

1,883

1,955

 

2,590 (41.5%)

3,461 (47.8%)

 

1,037

922

Malabsorption disorders

11 (2.2%)

1,864 

498 (71.8%)

860

PPI use

70 (3.2%)

2,058

2,173 (54.9%)

947 

African-American patients were less likely to be tested for B12 deficiency compared to other races (odds ratio [OR], 1.46; 95% CI, 1.402 to 1.514; p<0.001). Men were also less likely to be tested for vitamin B12 deficiency than women (p<0.05).

Patients with malabsorption disorders were more likely to be tested than the entire study population. Patients taking PPIs were also more likely to be tested for vitamin B12 deficiency; however, the deficiency rate was not statistically significant in these patients.

Of the 202 patients diagnosed with B12 deficiency, 105 charts were randomly reviewed to identify the most common reasons for vitamin B12 testing. Anaemia (26%), cognitive decline (17%), and neuropathy (16%) were the most commonly reported reasons, whereas only 3.8% stated that the B12 level was ordered for concern of deficiency caused by metformin.

Study Author Conclusions

These study findings suggest that physicians should be cognizant of the increased incidence of vitamin B12 deficiency in select populations. These populations include patients with greater than 5 years of metformin use and age greater than 65 years old. The patient’s race should also be considered.

InpharmD Researcher Critique

The study is unique as they distinguish the rates at which testing occurred and the rates at which populations were tested. In addition, the study is large and diverse, including more minorities other than just White patients. This study also accounted for confounders and excluded preexisting vitamin B12 deficiency. 

Limitations include not being able to address all potential confounders since this was an analysis of insurance claims. The study did not stratify patients based on metformin dosing or duration which may have also provided valuable information. This study was also an analysis of a single non-profit insurance plan in Michigan and the results may not apply to other areas.

 

References:

Martin D, Thaker J, Shreve M, Lamerato L, Budzynska K. Assessment of vitamin B12 deficiency and B12 screening trends for patients on metformin: a retrospective cohort case review. BMJ Nutr Prev Health. 2021;4(1):30-35. Published 2021 Jan 4. doi:10.1136/bmjnph-2020-000193

 

Evalution Of Vitamin B12 Monitoring In Patients On Metformin In Urban Ambulatory Care Settings

Design

Retrospective chart review

N= 322

Objective

To assess the occurrence of monitoring vitamin B12 levels in a diverse population

Study Groups

Vitamin B12 monitoring (n= 81)

No monitoring (n= 241)

Inclusion Criteria

Total daily metformin dose of ≥ 1000 mg for ≥ 6 months and a documented primary care provider visit during the year long study period

Exclusion Criteria

Diagnosis of type 1 diabetes, drug-induced diabetes, abnormal glucose elevations, prediabetes, polycystic ovarian syndrome, celiac disease, Crohn’s disease, Graves’ disease, chronic pancreatitis, alcoholism, human immunodeficiency virus (HIV), H.pylori infection, or pernicious anemia

Methods

Patient data was collected from six different ambulatory care sites focused on medically underserved populations. Patients were divided into those who had a vitamin B12 reading in the previous 5 years of index date versus those who did not.

Duration

January 1, 2017 to December 31, 2017

Primary Outcome

Primary: prevalence of normal (>350 pg/mL), low (200-350 pg/mL), and deficient (<200 pg/mL) vitamin B12 levels

   

 

 

 

Baseline Characteristics

 Patient Characteristics

Vitamin B12 monitoring (n= 81)

No monitoring (n= 241)

p-value

Age, years

69.23  56.42 <0.001

Female

61.7% 54.8% 0.34

Race, n

White

African american

Hispanic

Asian/pacific islander

Other

Declined

 

56.8%

25.9%

9.9%

2.5%

1.2%

3.7%

 

37.8%

27.4%

19.5%

7.5%

2.9%

5.0%

0.004

Metformin daily dose

1000 mg to < 2000 mg

≥ 2000 mg

 

44.4%

55.6%

 

42.7%

57.3%

0.89

B12 supplementation

27.2%

4.6%

<0.001

Results

Endpoint

Vitamin B12 monitoring (n= 81)

No monitoring (n= 241)

p-Value

Vitamin B12 monitoring

Normal levels

Low levels

Deficient levels

 

87.7%

11.1%

1.2%

 

--

 

Study Author Conclusions

In conclusion, the majority of patients at the FQHCs were not being monitored in accordance with the ADA guidelines. This revealed the need to educate providers and implement quality improvement projects to improve vitamin B12 monitoring in patients on chronic metformin therapy in ambulatory care settings. It would be beneficial for future studies to assess longitudinal vitamin B12 monitoring in order to better define the ideal frequency of vitamin B12 monitoring in patients with type 2 diabetes treated with metformin.

InpharmD Researcher Critique

The study primarily characterizes the patients who are likely to receive vitamin B12 monitoring and are less focused on the effect of metformin on vitamin B12 levels. A small sample size characterizing the Vitamin B12 monitoring group precludes analysis of metformin dose effect on vitamin B12 levels.

 

References:

Longo SL, Ryan JM, Sheehan KB, Reid DJ, Conley MP, Bouwmeester CJ. Evaluation of vitamin B12 monitoring in patients on metformin in urban ambulatory care settings. Pharm Pract (Granada). 2019 Jul-Sep;17(3):1499. doi: 10.18549/PharmPract.2019.3.1499. Epub 2019 Sep 13. PMID: 31592289; PMCID: PMC6763298.